Clinical profile and management of patients with acute myocardial infarction admitted to cardiac care units: The EYESHOT-2 registry.

Background: The clinical governance of patients with acute myocardial infarction (AMI) has markedly changed in the last few years. We sought to assess the contemporary in-hospital management patterns of patients with AMI at a country level.
Methods: EYESHOT (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units)-2 was a nationwide, prospective registry aimed to evaluate the current management of patients admitted to intensive cardiac care units (CCUs) for an AMI in Italy.
Results: Over a 4-week period (February 1st-29th, 2024), 183 CCUs enrolled 2806 consecutive patients: 52.6 % with non-ST elevation myocardial infarction (NSTEMI) and 47.4 % with ST-elevation myocardial infarction (STEMI). The median time from hospital admission to angiography in NSTEMI was 22.3 h (IQR 10.9-46.1), while for STEMI was 1.1 h (IQR 0.5-2.2) with significant difference between hospitals with and without catheterization laboratories. In both NSTEMI and STEMI patients, percutaneous coronary intervention (PCI) was the preferred management strategy (73.3 % and 94.2 %, respectively). An optimal secondary prevention therapy, including dual antiplatelet therapy, inhibition of the renin-angiotensin system, a beta-blocker and a high-intensity statin was prescribed at discharge in more than 75 % of patients with AMI. In-hospital major bleedings occurred in 2.0 % and 2.3 % (p = 0.58), while death in 1.8 % and 2.8 % (p = 0.09) of NSTEMI and STEMI patients, respectively.
Conclusions: The EYESHOT-2 registry shows the current management strategies and outcome of AMI patients admitted to Italian CCUs and provides insights to improve the clinical care of such patients.
Clinical Trial Registration: URL: http://www.
Clinicaltrials: gov. Unique identifier: NCT06316128.
Competing Interests: Declaration of competing interest LDL received honoraria for advisory boards or as speaker/chairman at scientific congresses from the following companies: Amgen, Aspen, AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, Daiichi Sankyo, Menarini, Novonordisk, Pfizer/Bristol-Myers Squibb, Sanofi and Servier. APM received personal fees for participation in study committees sponsored by Bayer, AstraZeneca, Novartis and Sanofi, outside the present work. SL received honoraria for advisory boards or as speaker/chairman at scientific congresses from the following companies: AstraZeneca, Boehringer Ingelheim, Chiesi, Daiichi Sankyo, Novonordisk, Pfizer/Bristol-Myers Squibb, and Sanofi. DL is an employee of Heart Care Foundation which conducted the study, partially supported by an unresctricted grant of research from Chiesi Farmaceutici S.p.A., Italy. MMG has no conflict of interest to disclose.
(Copyright © 2024 Elsevier B.V. All rights reserved.)